Is That Daylight for ImClone?
Is That Daylight for ImClone?
The beleaguered drugmaker finally gets some good news with Swiss approval of its cancer-fighting drug Erbitux
Is That Daylight for ImClone?
The beleaguered drugmaker finally gets some good news with Swiss approval of its cancer-fighting drug Erbitux
Over the Rainbow Yet?
Consolidation slows, valuations grow, and now hope for some IPOs
Ultimate Analysis
With the necessary tools at hand, the race is on to build � and market � the first affordable, portable, fully functional DNA analyzer. Is the world ready?
COUNTERING COUNTERFEITS
Industry offers proposals to fight growing problem of fake drugs.
BAYER CHEMICALS TO TAKE A SPIN
Split-off of chemicals will shift firm�s focus to life sciences
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Recent Comments